Session 1 of Bracken's Radiopharma Roundtable brought clinical, academic, and early-development leaders together to ask a hard question: are radiopharmaceutical trials becoming too complex to succeed? The consensus, and the way forward, are worth an hour of your time. Recorded June 11, 2026.
Endpoints have multiplied, procedures have piled up, and timelines have stretched. More endpoints mean more monitoring, more compliance failures, and a greater likelihood of trial delay, and eventually trial failure — not because the molecule fails, but because the data can't be acquired in time.
Imaging is the field's structural advantage. Because you can image, you can answer the early questions directly: does the tracer bind, is the tumor-to-kidney ratio favorable, what does dosimetry show. You can even fail a bad drug in Phase 1, which is rare in oncology and enormously valuable.
It's chalk and cheese: different radiation-safety demands, a fragile supply chain, and a different patient flow. The panel noted approved agents that stumbled precisely because they were forced into a conventional chemotherapy cycle. Fit-for-purpose beats retrofit.
Patient burden, cumulative dose to staff and family, and a scarce specialist workforce are design constraints, not footnotes. Discipline, fewer endpoints, and patient-centric design are how the field protects both sites and outcomes.
"This complexity must be actively managed to avoid running into the risks that we have seen time and time again."
"There is a human with cancer at the end of the needle. So, be mindful."
"We're very fortunate that we're dealing with biology and chemistry, but we also have physics on our side."
"It really is a key to us all to look for simpler, fit-for-purpose trial design, to really ensure that we enable success in this very rapidly evolving field."
We're picking up where the data left off: practical solutions for early-stage radiopharmaceutical development. Plus the questions we deliberately parked, including progression-free survival as a primary endpoint in RLT, and how to read RECIST when uptake within a single lesion is non-homogeneous. New panel, same candid format. Seats are open.
Subscribe to our monthly hand-crafted newsletter for the latest insights on clinical trial trends and the life science industry.
12 Penns Trail, Newtown, PA 18940
+1 215 648 1208
© 2026 the bracken group - Privacy Policy
12 Penns Trail, Newtown, PA 18940
+1 215 648 1208
© 2026 the bracken group - Privacy Policy
